Neurocrine Biosciences Inc
$ 162.71
1.15%
11 Jun - close price
- Market Cap 16,384,620,000 USD
- Current Price $ 162.71
- High / Low $ 164.04 / 160.18
- Stock P/E 25.11
- Book Value 33.87
- EPS 6.49
- Next Earning Report 2026-07-29
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.12 %
- ROE 0.22 %
- 52 Week High 169.57
- 52 Week Low 122.14
About
Neurocrine Biosciences, Inc., a biopharmaceutical company, discovers, develops, and markets pharmaceutical products for the treatment of neurological, endocrine, and psychiatric diseases and disorders in the United States. The company is headquartered in San Diego, California.
Analyst Target Price
$192.88
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-05 | 2026-02-11 | 2025-10-28 | 2025-07-30 | 2025-05-05 | 2025-02-06 | 2024-10-30 | 2024-08-01 | 2024-05-01 | 2024-02-07 | 2023-10-31 | 2023-08-01 |
| Reported EPS | 1.94 | 1.88 | 2.17 | 1.06 | 0.7 | 1.69 | 1.24 | 1.63 | 1.2 | 1.54 | 1.54 | 1.25 |
| Estimated EPS | 1.7 | 2.3 | 2.07 | 0.99 | 1.09 | 1.93 | 1.45 | 1.53 | 1.29 | 1.51 | 1.33 | 1.12 |
| Surprise | 0.24 | -0.42 | 0.1 | 0.07 | -0.39 | -0.24 | -0.21 | 0.1 | -0.09 | 0.03 | 0.21 | 0.13 |
| Surprise Percentage | 14.1176% | -18.2609% | 4.8309% | 7.0707% | -35.7798% | -12.4352% | -14.4828% | 6.5359% | -6.9767% | 1.9868% | 15.7895% | 11.6071% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-07-29 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | 1.78 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: NBIX
2026-06-12 07:01:46
Marquis Who's Who has recognized Noah Post for his distinguished career in pharmaceuticals, marked by over two decades of experience and leadership, primarily at Ionis Pharmaceuticals Inc. As an assistant director, he has overseen critical research, advanced innovative therapies, and holds a patent. His career highlights include a first-authored paper, developing drug discovery processes, and presenting at WRIB conferences.
2026-06-12 01:10:46
Neurocrine Biosciences (NBIX) has experienced recent share price momentum, closing at US$162.71, with significant short-term and long-term gains. Despite this, a valuation model suggests the stock is 15.6% undervalued, with a fair value of US$192.88, due to its diversified CNS pipeline and potential for future earnings growth. Investors are encouraged to consider the company's financial health, risks related to product pricing, and analyst assumptions when evaluating its investment potential.
2026-06-11 00:09:09
Neurocrine Biosciences' INGREZZA demonstrated strong symptom improvements in tardive dyskinesia for complex patients, including those with intellectual disabilities and hepatic impairment, reinforcing its value as a core commercial asset. The stock is currently trading at $160.86, showing a 14.4% year-to-date gain and is considered undervalued by Simply Wall St's analysis. This data provides further evidence of INGREZZA's broad applicability, supporting Neurocrine's valuation story.
2026-06-10 07:10:46
Neurocrine Biosciences' Chief Scientific Officer, Jude Onyia, reported a charitable gift of 2,441 shares of common stock on June 5, 2026. This transaction was not a market sale and involved no monetary value exchanged. Following the gift, Onyia directly holds 23,405 common shares of Neurocrine Biosciences.
2026-06-10 03:39:18
A director at Neurocrine Biosciences (NBIX.US) sold 30,000 shares of common stock for a total value of US$4.13 million. The sale price per share was US$137.66.
2026-06-10 00:39:18
Stephen A. Sherwin, a director at Neurocrine Biosciences Inc. (NASDAQ:NBIX), sold 25,000 shares of common stock worth approximately $4.13 million on June 5, 2026, though he also acquired the same number of shares through stock option exercises. The transactions were made under a Rule 10b5-1 trading plan. The article also mentions recent positive news for Neurocrine, including clinical data presentations for INGREZZA and CRENESSITY, and favorable coverage from Goldman Sachs and Bernstein.
